Open AccessLean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN
Author(s) -
David A. Iglesias,
Qian Zhang,
Joseph Celestino,
Charlotte C. Sun,
Melinda S. Yates,
Rosemarie Schmandt,
Karen H. Lu
Publication year - 2016
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000450615
Subject(s) - pten , medicine , endocrinology , adiponectin , metformin , endometrial cancer , pi3k/akt/mtor pathway , chemistry , insulin , insulin resistance , cancer , apoptosis , biochemistry
Obesity is a major risk factor for endometrial cancer. We evaluated whether obesity exacerbates progression of endometrial hyperplasia (EH) using the PRCre/+ PTENflox/+ mouse model and examined if the type 2 diabetes drug, metformin, could prevent EH.